Infection is the leading cause of death in multiple myeloma (MM). However, the cellular composition associated with immune dysfunction is not defined. We analyzed immune profiles in the peripheral blood of patients with MM (n = 28) and B-cell chronic lymphoproliferative disorders (n = 53) vs...
The case study included a 45-year-old man diagnosed with stage 3 multiple myeloma who was treated with bortezomib and dexamethasone. A case study suggests that although treatment of multiple myeloma (MM) with bortezomib can be beneficial, it can also simultaneously aggravate ...
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers. The report, published inBlood Advances, also suggests thatblood cancer patientsmay have a...
The article presets a case study of a 64-year-old man with multiple myeloma (MM). He exhibits lower back pain, fatigue, and renal failure, and illustrates a proliferation of monoclonal plasma cells. His serum monoclonal immunoglobulin G (IgG) protein level and bone marrow plasma cells show ...
During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with lenalidomide-refractory multiple myeloma after 1 prior line of therapy. Roundtable Roundup: Choosing a Bispecific Antibody for R/R Multiple Myeloma ...
The case records and the roentgenograms of the jaws of 59 patients with multiple myeloma were reviewed. Seventeen of these patients exhibited evidence of myeloma in the jaws. Among these 59 patients the ratio of males to females was approximately 2 to 1. However, among the patients with lesi...
Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1). J. Clin. Oncol. 41,Jco2200690 (2022). Berdeja, J. G. et al. Ciltacabtagene ...
Article IgE multiple myeloma: a new case report was published on February 1, 2017 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 55, issue 2).
Fibbe WE, Jansen J: Prognostic factors in IgD myeloma: study of 21 cases. Scand J Haematol. 1984, 33: 471-475. Article CAS PubMed Google Scholar Bladé J, Lust JA, Kyle RA: Immunoglobulin D multiple myeloma presenting features response to therapy, and survival in a series of 53 cases...
BackgroundMultiple myeloma (MM) is an incurable plasma cell malignancy with a poorly understood etiology. The purpose of our research was to examine the relationships between lifetime occupations and MM in a relatively large case–control study.MethodsMM cases (n=180) were identified through cancer...